J Clin Aesthet Dermatol. 2019;12(11):32–34 by Bruna Souza Felix Bravo, MD; Julien
J Clin Aesthet Dermatol. 2019;12(11):35–44 by Athanasios J. Stefanis, MD, MPharm; Tomas
Objective. We sought to evaluate the safety, tolerability, and patterns of use for the once-daily oral, narrow-spectrum antibiotic sarecycline in patients with moderate-to-severe acne vulgaris during a 40-week Phase III, multicenter, open-label extension study.